TAK vs. SNY, GSK, ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, and RDY
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Takeda Pharmaceutical vs. Its Competitors
Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.
Sanofi pays an annual dividend of $1.59 per share and has a dividend yield of 3.3%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.5%. Sanofi pays out 56.8% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Sanofi has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 2.36%. Sanofi's return on equity of 17.15% beat Takeda Pharmaceutical's return on equity.
In the previous week, Sanofi had 19 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Sanofi and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.67 beat Sanofi's score of 0.65 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Sanofi currently has a consensus target price of $61.50, suggesting a potential upside of 25.81%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.
Sanofi has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.
Summary
Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Takeda Pharmaceutical Competitors List
Related Companies and Tools
This page (NYSE:TAK) was last updated on 7/3/2025 by MarketBeat.com Staff